BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Avantra Biosciences Launches Multiplex System for Faster, Easier Quantification of Cancer Protein Biomarkers


1/26/2011 7:06:28 AM

WOBURN, Mass., Jan. 26, 2011 /PRNewswire/ -- Avantra® Biosciences, a leading innovator in protein diagnostics, announced today their first shipments of the new Q400 Biomarker Workstation and the innovative Angio Qx BioChip Immunoassay. The system provides quantitative protein biomarker results for ten analytes in less than an hour, requiring less than five minutes for sample preparation. Multiplex protein assays can be helpful in evaluating the association between elevated protein levels, patient phenotype and drug response.

The Angio Qx Immunoassay is a member of the Avantra QPDx biomarker detection product line for use with the Q400 Biomarker Workstation. This platform consists of a completely self-contained immunoassay BioChip and instrument, for use in the automated measurement of key biomarkers.

Avantra is currently working with leading experts and institutions on the development of additional biomarker panels directed at specific diseases with an emphasis in the field of oncology for research use only (RUO). Avantra intends to seek regulatory approval for its assay technologies in the future.

The power and simplicity of Avantra's QPDx platform offers users a rapid, easy-to-use, high quality bench top quantitative multiplex protein assay platform with extremely low CVs and very little setup time.

"The initial shipment of Avantra's QPDx biomarker product line represents the first milestone in Avantra's strategy to develop a suite of oncology focused multiplex biomarker panels. We see a tremendous opportunity for our QPDx product line and we are excited about the work we are doing with our partners to commercialize additional oncology specific biomarker panels," says Brian McKernan, CEO of Avantra.

About Avantra Biosciences Corporation

Avantra Biosciences is a privately held diagnostics company that has pioneered next-generation technology for protein biomarker analysis. Initially focused on oncology, Avantra's integrated system enables scientists and clinicians to perform multiplex biomarker analysis for research use only (RUO) from their lab bench or clinical trial site.

www.AvantraBio.com

Copyright © 2011 Avantra Biosciences Corporation. All rights reserved.

SOURCE Avantra Biosciences


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->